Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Mol Biol Rep ; 50(1): 167-172, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36319782

RESUMO

BACKGROUND: MicroRNAs (miRs) are involved in the autoimmune and neurological diseases, including multiple sclerosis (MS), through modulating post-transcriptional gene regulation. Accumulating evidence indicates that miR-10, miR-24a, miR-124, and miR-21 play an imperative role in MS pathogenesis. Therefore, the current research aimed to analyze the expression of the selected miRNAs for MS in Iranian population. METHODS AND RESULTS: Blood sample of 75 relapsing-remitting MS (RRMS) patients and 75 healthy individuals suffering no neurodegenerative illness was collected. Subsequently, the isolation of peripheral blood mononuclear cells (PBMCs) was performed by employing Ficoll-Hypaque density gradient method. Afterward, total RNA was extracted and subjected to qRT-PCR analysis. The obtained results evidenced that the relative expression of miR-10 (P = 0.0002), miR-21 (P = 0.0014), and miR-124 (P = 0.0091) significantly decreased in RRMS patients compared to healthy participants. On the contrary, no notable change was observed between the studies groups regarding miR-24a expression levels (P = 0.107). ROC curve analysis estimated an area under the curve (AUC) value equal to 0.75 with P = 0.0006 for miR-10, while it was decreased for miR-21 (AUC = 0.67 and P = 0.0054) and miR-124 (AUC = 0.66 and P = 0.012). CONCLUSION: The change in miR-10, miR-124, and miR-21 expression patterns was implied to participate in MS development. Further large scale observational studies are recommended.


Assuntos
MicroRNAs , Esclerose Múltipla Recidivante-Remitente , Esclerose Múltipla , Humanos , Esclerose Múltipla/genética , Esclerose Múltipla/metabolismo , Leucócitos Mononucleares/metabolismo , Irã (Geográfico) , MicroRNAs/metabolismo , Esclerose Múltipla Recidivante-Remitente/genética
2.
Psychiatr Genet ; 32(1): 25-29, 2022 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-34955516

RESUMO

BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder MicroRNAs (miRNAs) may be promising diagnostic biomarkers for AD. Previous evidence shows that miR-15b-5p, hsa-let7g-5p and hsa-let7d-5p might confer potential blood biomarkers for timely diagnosis of AD. Therefore, in this replication study, we aimed to investigate the serum transcript level of these miRNAs to assess for their potential as diagnostic or prognostic biomarker in AD patients. METHODS: Blood samples were obtained from 50 AD patients and 50 age- and sex-matched healthy individuals. Then, total RNA was extracted from serum samples, cDNA was synthesized, and the expression level of miRNAs was measured by the real-time PCR method. RESULTS: The expression level of hsa-let7d-5p (fold change = 2.14, P = 0.007) and hsa-let7g-5p (fold change = 1.94; P = 0.013) was significantly increased in the AD patients compared to control individuals. However, the difference in the transcription of miR-15b-5p between the two groups was not statistically significant (fold change = 1.08; P = 0.76). The AROC for transcript levels of hsa-let-7d-5p was 0.68 (P = 0.014; 95% CI, 0.39-0.88) and it was 0.64 for hsa-let-7g-5p (P = 0.028; 95% CI, 0.27-0.89). The cut-off value for let-7d-5p had 0.82 sensitivity and 0.34 specificity. Moreover, the cut-off value for hsa-let-7g-5p indicated a 0.79 sensitivity and 0.28 specificity. CONCLUSION: Our findings suggest the potential of measuring the transcript levels of hsa-let7d-5p and hsa-let7g-5p miRNAs as a diagnostic biomarker for AD.


Assuntos
Doença de Alzheimer , MicroRNAs , Doença de Alzheimer/genética , Biomarcadores , Humanos , MicroRNAs/sangue , MicroRNAs/genética
3.
J Gastrointest Cancer ; 52(1): 125-129, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31927744

RESUMO

PURPOSE: One of the most common cancers in the world is colorectal cancer, which has increased significantly in recent decades. In the carcinogenicity process in the colon, there are genes involved in various cellular processes, such as cell cycle, apoptosis, and cell migration. According to studies carried out, both miR-506 and SPON 1 genes are involved in the process which initiates and promotes cancer. In this study, alterations in the expression of target genes from the viewpoint of carcinogenicity were studied and evaluated. METHODS: Fifty tumor tissues and normal marginal tissue were collected from patients who were undergoing colorectal cancer surgery. After the extraction of RNA, the real-time PCR method was performed to evaluate the gene expression. Also, alterations of gene expression in response to defined amounts of chemotherapeutic drugs (IC50) were evaluated. P < 0.05 was considered statistically significant. RESULTS: The relative expression level of miR-506 in tumor tissues was significantly decreased in comparison with healthy marginal tissues (P = 0.044). On the other hand, the SPON1 gene expression level was decreased too in tumor tissues in comparison with healthy marginal tissues (P = 0.019). There was also a significant relationship between the expression of target genes and clinicopathological involvement. However, there was no significant alteration in these genes along with the chemotherapeutic drug. CONCLUSION: These findings suggest that the relative expression of miR-506 and SPON 1 gene can be considered as a diagnostic or predictive biomarker for colorectal cancer. However, further studies on protein levels should be conducted.


Assuntos
Biomarcadores Tumorais/metabolismo , Neoplasias Colorretais/genética , Proteínas da Matriz Extracelular/genética , Neoplasias Hepáticas/epidemiologia , MicroRNAs/metabolismo , Adulto , Idoso , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Biomarcadores Tumorais/genética , Carcinogênese/genética , Linhagem Celular Tumoral , Quimioterapia Adjuvante/métodos , Colectomia , Colo/diagnóstico por imagem , Colo/patologia , Colo/cirurgia , Colonoscopia , Neoplasias Colorretais/diagnóstico , Neoplasias Colorretais/terapia , Regulação para Baixo , Feminino , Fluoruracila/farmacologia , Fluoruracila/uso terapêutico , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Mucosa Intestinal/diagnóstico por imagem , Mucosa Intestinal/patologia , Mucosa Intestinal/cirurgia , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/secundário , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Oxaliplatina/farmacologia , Oxaliplatina/uso terapêutico , Prognóstico
4.
Psychiatr Genet ; 30(6): 162-165, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-33079740

RESUMO

Introduction Schizophrenia is recognized as one of the most important mental illnesses of the last century. Many genetic and environmental factors are involved in this condition. Recently, the genome-wide association study identified two significant genes LRP8 and CEP85L associated with psychiatric disorders. LRP8 (low-density lipoprotein receptor-related protein 8) acts as a cytoplasmic receptor for Reelin. Many studies have revealed that LRP8 was significantly related to schizophrenia and bipolar disorder in Chinese population. CEP85L standing for 'centrosomal protein 85 kDa-like' is another gene, which has been reportedly associated with BPD. Methods We performed a case-control study to analyze the association between rs5177 single-nucleotide polymorphism in the LRP8 gene plus the single-nucleotide polymorphism rs11756438 in the CEP85L gene and schizophrenia in the Iranian population. The genotype for rs5177 was determined by ARMS PCR method, while for rs11756438 genotype, it was determined by PCR-RFLP method after which statistical analysis was performed for each polymorphism. In rs5177, the CC genotype was susceptible to the disease while G allele was associated with disease protection. Results and Conclusion In rs11756438, the AA genotype was associated with disease susceptibility, while allele A did not have a significant association with the disease.


Assuntos
Proteínas do Citoesqueleto/genética , Proteínas Relacionadas a Receptor de LDL/genética , Proteínas de Fusão Oncogênica/genética , Polimorfismo de Nucleotídeo Único , Esquizofrenia/genética , Regiões 3' não Traduzidas/genética , Adulto , Alelos , Estudos de Casos e Controles , Feminino , Frequência do Gene , Predisposição Genética para Doença , Genótipo , Humanos , Íntrons/genética , Irã (Geográfico)/epidemiologia , Masculino , Modelos Genéticos , Reação em Cadeia da Polimerase , Polimorfismo de Fragmento de Restrição , Proteína Reelina , Esquizofrenia/epidemiologia
5.
Life Sci ; 254: 117580, 2020 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-32205087

RESUMO

Dendritic cells (DCs) are considered as professional antigen presenting cells (APCs), containing a variety of subsets, that can be resident in organs or migrating among the lymphoid and non-lymphoid organs. In a normal steady condition, DCs concomitantly process and present antigens on major histocompatibility complex (MHC) class I and II. However, they are further activated after exposing to antigens. Recently, several approaches have been exerted to improve antigen presentation potency, to elicit powerful immune responses against tumor cells. In DC-based cancer immunotherapy, DC is obtained from patient and modulated ex vivo in order to entice the immune system toward tumor elimination. Several approaches have been on the evaluation for long-term anti-tumor immune responses by DCs. On the other side, combination of DC vaccines with other cancer therapies, like chemotherapy and monoclonal antibodies could confer efficient cancer therapeutics. In this review article, we first go through the immunobiology of DC, and development of DC vaccines. Then, we concentrate on the DC immunotherapy by highlighting combinational approaches to enhance the efficacy of cancer treatment strategies.


Assuntos
Células Dendríticas/imunologia , Imunoterapia , Neoplasias/terapia , Adjuvantes Imunológicos/uso terapêutico , Apresentação de Antígeno/imunologia , Terapia Combinada , Humanos , Neoplasias/imunologia , Radioterapia , Microambiente Tumoral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA